Brokerages Set Insmed, Inc. (NASDAQ:INSM) Target Price at $212.50

Shares of Insmed, Inc. (NASDAQ:INSM) have earned an average rating of “Moderate Buy” from the twenty-five research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, twenty-three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $211.8636.

A number of brokerages have weighed in on INSM. Wells Fargo & Company lowered their price target on Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Royal Bank Of Canada lowered their price target on Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. JPMorgan Chase & Co. lowered their price target on Insmed from $180.00 to $179.00 and set an “overweight” rating on the stock in a research report on Monday, June 8th. Roth Mkm reissued a “buy” rating on shares of Insmed in a research report on Monday, June 8th. Finally, Mizuho set a $192.00 price target on Insmed in a research report on Tuesday, June 16th.

Insmed Stock Performance

Shares of INSM stock opened at $98.61 on Tuesday. The company has a fifty day moving average price of $116.75 and a two-hundred day moving average price of $146.26. Insmed has a one year low of $90.39 and a one year high of $212.75. The stock has a market cap of $21.37 billion, a P/E ratio of -17.15 and a beta of 0.79. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same period in the previous year, the business earned ($1.42) EPS. Insmed’s revenue for the quarter was up 229.7% compared to the same quarter last year. As a group, equities analysts predict that Insmed will post -2.54 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Sara Bonstein sold 2,404 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $245,857.08. Following the transaction, the chief financial officer owned 69,082 shares in the company, valued at approximately $7,065,016.14. This represents a 3.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the transaction, the chief executive officer owned 301,185 shares in the company, valued at approximately $43,361,604.45. This trade represents a 3.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 149,783 shares of company stock worth $22,902,672 in the last three months. 2.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently made changes to their positions in INSM. Empowered Funds LLC increased its stake in shares of Insmed by 32.6% during the first quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company’s stock worth $8,501,000 after purchasing an additional 12,775 shares during the period. Defilade Capital Management L.P. increased its stake in shares of Insmed by 289.8% during the first quarter. Defilade Capital Management L.P. now owns 194,909 shares of the biopharmaceutical company’s stock worth $31,872,000 after purchasing an additional 144,909 shares during the period. Parallel Advisors LLC increased its stake in shares of Insmed by 13.1% during the first quarter. Parallel Advisors LLC now owns 2,291 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 266 shares during the period. NewEdge Advisors LLC increased its stake in shares of Insmed by 133.0% during the first quarter. NewEdge Advisors LLC now owns 6,015 shares of the biopharmaceutical company’s stock worth $984,000 after purchasing an additional 3,433 shares during the period. Finally, NWI Management LP increased its stake in shares of Insmed by 2.6% during the first quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock worth $165,809,000 after purchasing an additional 25,540 shares during the period.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.